ATECHealthcare · Medical DevicesThe 14 Wall Street analysts covering Alphatec Holdings, Inc. hold a median 12-month price target of $14 — +68.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 60 of 100 as at 3 Nov 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Alphatec Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (90): The business earns solid, repeatable profits on what it owns.
Revisions (33): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ATEC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +68.9% from it.
Of the 20 most recent actions, 3 moved their price target up and 6 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 31 Oct 2026 | Canaccord Genuity | Maintains | Buy | — |
| 30 Oct 2026 | Canaccord Genuity | Maintains | Buy | $19 → $16 |
| 30 Oct 2026 | JP Morgan | Maintains | Overweight | $16 → $15 |
| 30 Oct 2026 | Needham | Maintains | Buy | $14 → $12 |
| 30 Oct 2026 | TD Cowen | Maintains | Buy | $13 → $10 |
| 30 Oct 2026 | Wells Fargo | Maintains | Overweight | $14 → $12 |
| 5 Aug 2026 | BMO Capital | Maintains | Outperform | $11 → $12 |
| 5 Aug 2026 | BMO Capital | Maintains | Outperform | — |
| 5 Aug 2026 | TD Cowen | Maintains | Buy | $11 → $13 |
| 5 Aug 2026 | TD Cowen | Maintains | Buy | — |
| 5 Aug 2026 | UBS | Maintains | Buy | $15 → $16 |
| 5 Aug 2026 | UBS | Maintains | Buy | — |
| 28 July 2026 | UBS | Initiates | Buy | — |
| 28 July 2026 | UBS | Initiates | Buy | $15 |
| 23 July 2026 | Stephens & Co. | Initiates | Overweight | $15 |
| 23 July 2026 | Stephens & Co. | Initiates | Overweight | — |
| 9 July 2026 | BMO Capital | Initiates | Outperform | $11 |
| 9 July 2026 | BMO Capital | Initiates | Outperform | — |
| 8 July 2026 | Stifel | Maintains | Buy | $16 → $13 |
| 8 July 2026 | Stifel | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ATEC appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Alphatec Holdings, Inc. returned −57.3% against +12.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 92% of US stocks
Cheaper than 61% of US stocks
Cheaper than 99% of US stocks
Cheaper than 7% of US stocks
Higher than 59% of US stocks
Higher than 54% of US stocks
Higher than 85% of US stocks
Higher than 48% of US stocks
Higher than 20% of US stocks
Higher than 5% of US stocks
Higher than 37% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Alphatec Holdings, Inc. has a market value of $1.1B and an enterprise value of $1.7B.
Revenue in the twelve months to 30 June 2026: $815.1M. The latest quarter grew 12.6% year on year.
Net income over the same four quarters: −$110.0M, a −13.5% net margin.
Diluted earnings per share, trailing twelve months: $−0.71.
Free cash flow in the twelve months to 30 June 2026: −$5.7M.
Trailing P/E: −7.8×; forward P/E: 13.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Alphatec Holdings, Inc. employs 913 people — $893K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Alphatec Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Business Wire published a notice that ATEC investors have an opportunity to join a fraud investigation involving Alphatec Holdings, Inc., with SBS Law.
Why it matters — The notice concerns a fraud investigation involving Alphatec Holdings and may be relevant to investors following the company.
Levi & Korsinsky announced an investigation on behalf of Alphatec Holdings shareholders who lost money. The notice cites the company’s revision of 2026 revenue guidance from approximately $882 million to approximately $862 million after its third-quarter results.
Why it matters — The investigation notice and lower revenue outlook are developments ATEC watchers may wish to follow.
Alphatec cut its full-year outlook as fewer surgeons purchased its add-on bone-graft products used for spinal fusion. The Barron’s headline reports a 32% plunge in the stock.
Why it matters — The weaker demand for bone-graft products and reduced outlook are relevant to ATEC watchers assessing the company’s business performance.
Seeking Alpha published a transcript of Alphatec Holdings, Inc.’s Q3 2026 earnings call. The excerpt provides no details about the discussion.
Why it matters — ATEC watchers can note that a transcript of the company’s quarterly earnings call is available, though the excerpt gives no specific results or commentary.
Alphatec reported third-quarter revenue growth and expanded profitability, but lowered its full-year outlook. The company cited weaker biologics performance, softer thoracolumbar procedure volumes and a temporary international supply constraint.
Why it matters — ATEC watchers may weigh the quarterly growth and improved profitability against the reduced outlook and the operating factors behind it.
The 14 Wall Street analysts covering Alphatec Holdings, Inc. have a median 12-month price target of $14, with estimates ranging from $8 to $24. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 14 analysts covering Alphatec Holdings, Inc., 13 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Alphatec Holdings, Inc. 60 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, Alphatec Holdings, Inc. ranks 60 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (90 of 100).
No one can know that. What the data says: the median 12-month target from 14 analysts implies +68.9% from the last close, and Ticker Nerd's factor model ranks Alphatec Holdings, Inc. 60 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Alphatec Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ATEC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $24 over the next 12 months.
Alphatec Holdings, Inc. returned -57.3% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Alphatec Holdings, Inc. is a medical technology company focused on the surgical treatment of spinal disorders.
The most recent item we track (Business Wire, 4 Nov 2026): "ATEC Investors Have Opportunity to Join Alphatec Holdings, Inc. Fraud Investigation with SBS Law". Business Wire published a notice that ATEC investors have an opportunity to join a fraud investigation involving Alphatec Holdings, Inc., with SBS Law.
Alphatec Holdings, Inc. is a medical technology company focused on the surgical treatment of spinal disorders. Alphatec Holdings, Inc. develops and commercializes a broad portfolio of spine-care products and procedural solutions, including spinal implants, fixation systems, access instruments, biologics, imaging systems, and neuromonitoring technologies. Its offerings are designed to support surgeons across the full workflow of spine procedures, from preoperative planning and intraoperative guidance to reconstruction and stabilization. The company’s product ecosystem includes the EOS imaging platform, SafeOp neural monitoring, and Valence navigation and robotics, alongside implant and biologics lines used in fusion and deformity procedures. Alphatec Holdings, Inc. serves hospitals, surgeons, and other healthcare providers in the United States and internationally, with a business centered on improving the precision, reproducibility, and clinical workflow of spine surgery.
CEO Mr. Patrick S. Miles · 913 employees · United States · https://www.atecspine.com
